VESIcare FDA Approval History
FDA Approved: Yes (First approved November 19, 2004)
Brand name: VESIcare
Generic name: solifenacin succinate
Dosage form: Tablets
Company: Astellas Pharma US, Inc.
VESIcare (solifenacin) is a muscarinic receptor antagonist for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.
VESIcare LS is an oral suspension formulation of solifenacin for the treatment of neurogenic detrusor overactivity in pediatric patients aged 2 years and older.
Development Timeline for VESIcare
|May 27, 2020||FDA Approves VESIcare LS (solifenacin succinate) Oral Suspension for Neurogenic Detrusor Overactivity (NDO) Pediatric Patients|
|Nov 19, 2004||FDA Approves Vesicare (solifenacin succinate) for the Treatment of Overactive Bladder|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.